Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

ER study pits haloperidol vs olanzapine for cannabis vomiting crisis

NCT ID NCT07246187

Symptom relief Sponsor: Mercy Bon Secours Saint Vincent Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether haloperidol or olanzapine works better to quickly reduce nausea, vomiting, and belly pain in people with cannabinoid hyperemesis syndrome (CHS) who come to the emergency department. About 114 frequent cannabis users will receive one of the two drugs as a shot, and their symptoms will be tracked on a 0-10 scale. The goal is to find which medication offers faster relief and helps patients avoid hospital admission.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
haloperidol and olanzapine (antipsychotic drugs given as injections)
What this could lead to
If it works, this could identify a better, faster way to relieve severe nausea and abdominal pain for people with cannabinoid hyperemesis in the emergency room.
What could go wrong
This is a relatively small trial (114 people) testing two existing drugs, so the results may not apply to all patients. Both drugs have side effects like drowsiness or movement issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 114 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * subjects must meet ONE of the below criteria AND are a near-daily to daily user of cannabis by inhalation for greater than or equal to 6 months. 1. Have documented previous diagnosis of cannabinoid hyperemesis, or 2. Report (or on chart review) greater than or equal to 3 episodes of emesis in a cyclic pattern separated by greater than 1 month during the preceding 2 years, or 3. The provider suspects cannabinoid hyperemesis as the primary or equally likely primary diagnosis. Exclusion Criteria: * Ineligible subjects include age less than 18 years, weight less than 50 kg, pregnancy, daily benzodiazepines use, prolonged QTc interval on the electrocardiogram (ECG), breastfeeding mothers, previously known allergy to or intolerance of either study drug, subjects taking drugs that are contraindicated with haloperidol or olanzapine, subjects with Parkison's Disease, subjects already taking haloperidol, olanzapine, or other antipsychotics

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cannabinoid hyperemesis syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cannabinoid hyperemesis syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cannabinoid hyperemesis syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Mercy Saint Vincent Medical Center

    RECRUITING

    Toledo, Ohio, 43608, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.